Nerlynx (neratinib) Prior Authorization
Customize your policy alerts
Sign up for all Colorado Rocky Mountain Health Plans policy alerts
Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and notification requirements for Nerlynx (neratinib) for members receiving treatment for breast cancer or cervical cancer. Members under age 19 process automatically without coverage review, while other members must meet the applicable clinical criteria.
The brain metastases criteria were updated to recognize Nerlynx use with ado-trastuzumab emtansine, capecitabine, or paclitaxel for HER2-positive breast cancer with brain metastases.
The clinical background and references were updated during the annual review.
Coverage criteria include recurrent or metastatic HER2-positive cervical cancer treated with Nerlynx as second-line or subsequent therapy.
Coverage criteria include extended adjuvant Nerlynx therapy for selected patients with node-positive, hormone receptor-positive, HER2-positive breast cancer at high risk of recurrence.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.